French independent pharma firm Servier today published its results for the 2020/21 financial year, ending on September 30, 2021.
Servier Group revenue for the 2020/21 financial year increased by 4.3% compared to 2019/20 at constant exchange rates (+0.8% at current rates) to reach 4.725 billion euros ($5.4 billion).
2020/21 earnings before interest, taxes, depreciation and amortization (EBITDA) remains stable compared to the previous financial year at 625 million euros, representing 13.2% of group revenue, as well as the operating income which amounts to 278 million euros, ie, 5.9% of group revenue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze